Gardiner S M, March J E, Kemp P A, Davenport A P, Bennett T
School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH.
Br J Pharmacol. 2001 Apr;132(8):1625-9. doi: 10.1038/sj.bjp.0704051.
The regional haemodynamic effects of rat or human urotensin II (U-II) 3, 30, 300 and 3000 pmol kg(-1), i.v.) were assessed in separate groups of conscious, unrestrained, male, Sprague-Dawley rats (n=8 in each). Rat and human U-II had similar effects. At a dose of 3 pmol kg(-1), neither peptide had any significant action, while at a dose of 30 pmol kg(-1), there was a transient mesenteric vasodilatation (significant only for rat U-II). At doses of 300 and 3000 pmol kg(-1), there were dose-dependent tachycardias, and mesenteric and hindquarters hyperaemic vasodilatations. Thus, in conscious rats, the predominant cardiovascular action of rat and human U-II is vasodilatation. This is in contrast to recent findings with human U-II in non-human primates, but is consistent with effects on human isolated resistance vessels.
分别在清醒、未束缚的雄性Sprague-Dawley大鼠组（每组n = 8）中评估大鼠或人尾加压素II（U-II，静脉注射，剂量为3、30、300和3000 pmol kg⁻¹）的局部血流动力学效应。大鼠和人U-II具有相似的效应。在3 pmol kg⁻¹的剂量下，两种肽均无任何显著作用，而在30 pmol kg⁻¹的剂量下，出现短暂的肠系膜血管舒张（仅大鼠U-II显著）。在300和3000 pmol kg⁻¹的剂量下，出现剂量依赖性心动过速以及肠系膜和后肢充血性血管舒张。因此，在清醒大鼠中，大鼠和人U-II的主要心血管作用是血管舒张。这与最近在非人灵长类动物中关于人U-II的研究结果相反，但与对人离体阻力血管的作用一致。
